A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer-Reference-Cited by-同舟云学术

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer

Published:2024-07 Issue: Volume:154 Page:106861
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Desilets Antoine^ORCID,Pfister David G.,Stein Sarah,Wong Winston,Sherman Eric J.,Fetten James,Hung Tony K.W.,Kriplani Anuja,Dunn Lara A.,Ho Alan L.,Michel Loren S.

Funder

National Cancer Institute

National Institutes of Health

Exelixis Inc

Publisher

Elsevier BV

Reference25 articles.

1. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. Jan 29 2015;517(7536):576-82. doi:10.1038/nature14129.

2. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy;Ang;Int J Radiat Oncol Biol Phys,2004

3. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma;Ang;Cancer Res,2002

4. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer;Vermorken;N Engl J Med,2008

5. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter to the editor “A phase 1 study of concurrent cabozantinib and cetuXimab in recurrent or metastatic head and neck squamous cell cancer”;Oral Oncology;2024-10